Acumen Pharmaceuticals, Inc. (ABOS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US00509G2093
Acumen Pharmaceuticals, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -123.83 m USD |
| EBIT | -124.56 m USD |
| Net income | -121.34 m USD |
| Diluted EPS – continuing operations | -2.00 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
More stocks
- Marker Therapeutics, Inc. (MRKR)
- Norris Industries, Inc. (NRIS)
- ASHFORD HOSPITALITY TRUST INC (AHT)
- Galenfeha, Inc. (NGHI)
- Karbon-X Corp. (KARX)
- MERCER INTERNATIONAL INC. (MERC)
- Citius Pharmaceuticals, Inc. (CTXR)
- FIREFLY NEUROSCIENCE, INC. (AIFF)
- Allarity Therapeutics, Inc. (ALLR)
- TAO Synergies Inc. (TAOX)
- Tvardi Therapeutics, Inc. (TVRD)
- Teads Holding Co. (TEAD)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.